Scavenger Receptor B2/CD36 Monoclonal Antibody (Clone JC63.1) (Low Endotoxin)

CD36, also known as scavenger receptor B2 or fatty acid translocase, is a transmembrane glycoprotein that has roles in fatty acid uptake and lipid metabolism and signaling.¹ It is composed of N- and C-terminal cytoplasmic tails, two transmembrane domains, and an extracellular loop that binds to a variety of lipid ligands, including long-chain fatty acids, oxidized LDL, and oxidized phospholipids, and protein ligands, such as thrombospondin (TSP-1), and is subject to post-translational modifications.^1,2,3 CD36 is expressed by a variety of cells, including hematopoietic cells such as platelets, monocytes, and macrophages, as well as adipocytes, enterocytes, cardiac and skeletal myocytes, and endothelial and epithelial cells.^1,4 It also exists as a soluble form, sCD36, which is produced via plasma proteases.² CD36 expression is regulated by several transcription factors, including peroxisome proliferator-activated receptor (PPAR), STAT3, and hypoxia-inducible factor-1α (HIF-1α), in a tissue-dependent manner.^1,3 It is localized to the plasma membrane and within endosomes, the endoplasmic reticulum, and mitochondria, and is translocated between these compartments in response to various stimuli, including insulin-induced PI3K signaling and muscle contraction-induced AMPK signaling, to regulate fatty acid uptake.^2,3 It has additional roles in the phagocytosis of apoptotic cells and P. falciparum-infected red blood cells (RBCs), angiogenesis, thrombosis, inflammation, and atherosclerosis, as well as cancer metastasis.^3,5 Cayman's Scavenger Receptor B2/CD36 Monoclonal Antibody (Clone JC63.1) (Low Endotoxin) can be used for flow cytometry (FC) and immunocytochemistry (ICC) applications that require endotoxin levels of ≤2 EU/mg. Lower endotoxin levels can be achieved upon request.

WARNING This product is not for human or veterinary use.

1. Glatz, J.F.C., and Luiken, J.J.F.P. Dynamic role of the transmembrane glycoprotein CD36 (SR-B₂) in cellular fatty acid uptake and utilization. J. Lipid Res. 59(7), 1084-1093 (2018).

2. Wang, J., and Li, Y. CD36 tango in cancer: Signaling pathways and functions. Theranostics 9(17), 4893-4908 (2019).

3. Yang, X., Okamura, D., Lu, X., et al. CD36 in chronic kidney disease: Novel insights and therapeutic opportunities. Nat. Rev. Nephrol. 13(12), 769-781 (2017).

4. Glatz, J.F.C., and Luiken, J.J.F.P. From fat to FAT (CD36/SR-B₂): Understanding the regulation of cellular fatty acid uptake. Biochimie 136, 21-26 (2017).

5. Maréchal, L., Laviolette, M., Rodrigue-Way, A., et al. The CD36-PPARγ pathway in metabolic disorders. Int. J. Mol. Sci. 19(5), 1529 (2017).

Pascual, G., Avgustinova, A., Mejetta, S., et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 541(7635), 41-45 (2017).